IV 
109TH CONGRESS 
1ST SESSION 
H. RES. 421
Commending the Biotechnology Industry Organization, the world’s largest 
biotechnology organization, for a successful annual convention in Phila-
delphia, Pennsylvania. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 29, 2005
Ms. SCHWARTZ of Pennsylvania (for herself, Mr. DENT, Mr. BRADY of Penn-
sylvania, Mr. PAYNE, Mr. FITZPATRICK of Pennsylvania, Mr. SHERWOOD, 
Mr. CASTLE, Mr. HOLT, Mr. FATTAH, Mr. PASCRELL, Mr. MURTHA, Mr. 
LARSON of Connecticut, Mr. DOYLE, Mr. HOLDEN, Mr. KANJORSKI, Mrs. 
MCCARTHY, Mr. MOLLOHAN, Mr. ROTHMAN, Mr. MENENDEZ, Mr. KIND, 
Mrs. TAUSCHER, Mr. CROWLEY, Mrs. DAVIS of California, Mr. GERLACH, 
Mr. PALLONE, Mr. BISHOP of New York, Ms. HARMAN, Mr. HIGGINS, 
Mr. KILDEE, Ms. SOLIS, Ms. VELA´ZQUEZ, Mrs. NAPOLITANO, Ms. ROY-
BAL-ALLARD, Mr. WELDON
of Pennsylvania, Ms. BERKLEY, Mr. 
CARDOZA, Mr. SMITH of Washington, Mr. CARNAHAN, Mr. CLEAVER, Mr. 
SCHIFF, Ms. HOOLEY, Ms. DEGETTE, Mr. MOORE of Kansas, Mr. VAN 
HOLLEN, Mr. FORD, Mr. DAVIS of Tennessee, Mr. SCOTT of Virginia, 
Mr. OLVER, Mr. CHANDLER, Mr. AL GREEN of Texas, Mr. LOBIONDO, 
and Mr. FRELINGHUYSEN) submitted the following resolution; which was 
referred to the Committee on Government Reform 
RESOLUTION 
Commending the Biotechnology Industry Organization, the 
world’s largest biotechnology organization, for a success-
ful annual convention in Philadelphia, Pennsylvania.
Whereas the Biotechnology Industry Organization (‘‘BIO’’), 
the world’s largest biotechnology organization, provides 
advocacy, business development, and communications
•HRES 421 IH 
services for more than 1,100 biotechnology companies, 
academic institutions, state biotechnology centers, and re-
lated organizations across the United States and 31 other 
nations; 
Whereas biotechnology research expands the boundaries of 
science to benefit mankind by providing for better 
healthcare, enhanced agriculture, and a cleaner and safer 
environment; 
Whereas the convergence of systems biology, genomics, 
infomatics, proteomics, nanotechnology, and personalized 
medicine bring us to the threshold of a new era; 
Whereas biotechnology therapeutics are used to treat many 
diseases, including anemia, cystic fibrosis, growth defi-
ciency, rheumatoid arthritis, hemophilia, hepatitis, trans-
plant rejection, leukemia, and other cancers; 
Whereas there are more than 300 biotech drug products and 
vaccines currently in clinical trials targeting more than 
200 diseases, including various cancers, Alzheimer’s dis-
ease, heart disease, diabetes, multiple sclerosis, AIDS, 
and arthritis; 
Whereas biotechnology is responsible for hundreds of medical 
diagnostic tests that keep the blood supply safe from the 
AIDS virus and detect other conditions early enough to 
be successfully treated; 
Whereas environmental biotechnology products make it pos-
sible to clean up hazardous waste more efficiently by har-
nessing pollution-eating microbes without the use of caus-
tic chemicals; 
Whereas industrial biotechnology applications have led to 
cleaner processes that produce less waste and use less en-
ergy and water in such industrial sectors as chemicals,
•HRES 421 IH 
pulp and paper, textiles, food, energy, and metals and 
minerals; 
Whereas industrial biotechnology also enables its users to 
harness enzymes to convert plant waste to fuel and to 
biodegradable plastics, reducing our dependence on for-
eign oil; 
Whereas agriculture biotechnology allows its users to produce 
more and more healthful foods, on a fixed amount of ara-
ble land, in a more efficient manner, and these break-
throughs reduce soil tillage, fossil fuel use, and runoff of 
agricultural pesticides into our lakes, streams, and 
oceans; 
Whereas BIO brought together more than 18,700 people 
from 56 countries and all 50 States at its annual inter-
national convention in Philadelphia, Pennsylvania, from 
June 19 through June 22, 2005; 
Whereas the Commonwealth of Pennsylvania, the State of 
Delaware, and the State of New Jersey co-hosted the 
convention, known as the BIO 2005 Annual International 
Convention; 
Whereas more than 300 volunteers from this tri-State region 
and hundreds of employees of the City of Philadelphia 
contributed to the Convention’s success; 
Whereas the immediate economic impact of the BIO 2005 
Annual International Convention on the City of Philadel-
phia, including its hotels, restaurants, and taxi operators, 
is estimated at more than $35 million; 
Whereas the Convention put the local life-sciences community 
on the map globally; and 
Whereas the BIO 2005 Annual International Convention will 
allow for further collaboration, advancement, and devel-
•HRES 421 IH 
opment within the field of biotechnology: Now, therefore, 
be it
Resolved, That the House of Representatives com-
mends the Biotechnology Industry Organization for a suc-
cessful 2005 Annual International Convention at the 
Pennsylvania Convention Center in the City of Philadel-
phia.
Æ